Dyspareunia Treatment Market is Anticipated to Witness Growth Owing to Increasing Prevalence of Wome

Author : Vedant B | Published On : 12 Apr 2024

The dyspareunia treatment market is used for treatment of dyspareunia or pain experienced during sexual intercourse. Dyspareunia arises due to various medical conditions in women including endometriosis, pelvic inflammatory disease, sexual problems, vaginal atrophy, dryness or pain. Growing prevalence of women's health conditions like vulvodynia, endometriosis, and painful bladder syndrome increases chances of developing dyspareunia. Thus, growing women's health concerns worldwide is anticipated to contribute significantly to market growth over the forecast period.

The global dyspareunia treatment market is estimated to be valued at US$ 1,035.4 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024 to 2031. Dyspareunia Treatment Market includes hormonal therapy, pain management therapy, vaginal lubricants or moisturizers. These treatments help address root cause of pain and improve sexual functioning. Increasing adoption of non-hormonal localized therapies with minimal side effects is gaining popularity over systemic hormonal therapies.

Key Takeaways
Key players operating in the dyspareunia treatment market are Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International. These players are focusing on new product launches, acquisitions, and geographic expansions to increase their market share.
Growing prevalence of vulvodynia and other causes of dyspareunia offer significant growth opportunities in the market. According to the International Society for the Study of Vulvovaginal Disease, 8-12% of women experience vulvodynia at some point in their lives. Increasing diagnosis and awareness can help address unmet needs.
North America dominates the global dyspareunia treatment market due to growing preference for non-hormonal therapies and availability of advanced treatment options. However, Asia Pacific is expected to witness high growth owing to improving access to healthcare and increasing discretionary spending on women's health. Support from bodies like the WHO for women's health programs can help accelerate regional market growth.

Market Drivers
Increasing prevalence of endometriosis is a key driver as it is one of the leading causes of dyspareunia. According to Endometriosis Foundation of America, around 176 million women globally suffer from endometriosis.
Growing awareness about women's sexual health issues and availability of effective non-hormonal therapies are encouraging more women to seek medical help for dyspareunia. This drives the demand for therapy options.

Market Restraints
Higher costs associated with localized therapies restricts their widespread adoption in developing regions. Availability of generic alternatives also poses pricing challenges.
Social stigma associated with open discussion on sexual health issues in developing countries discourages women from timely diagnosis and treatment seeking behavior. This hampers market growth.

Segment Analysis
The dyspareunia treatment market is segmented into superficial dyspareunia and deep dyspareunia. Superficial dyspareunia dominates the market as it accounts for over 60% of total cases. This is due to factors like vaginal dryness, lack of lubrication, irritation in the vaginal tissues and infections which commonly cause pain in the outer vaginal area. The vaginal hormonal therapies, moisturizers and lubricants are effective in treating superficial dyspareunia which has contributed to its market dominance.

Global Analysis
North America holds the largest share in the dyspareunia treatment market owing to high per capita health expenditure and adoption of new drug therapies. However, Asia Pacific region is expected witness fastest growth during the forecast period due to rising awareness, improving access to treatment and expanding healthcare infrastructure in countries like China and India. The demand for therapeutics is also increasing in Latin America and Middle East & Africa regions due to growing prevalence of dyspareunia caused by post-menopausal changes and infections. Region-wide regulatory policies too have promoted the use of advanced drugs in managing gynecological disorders.

Get more insights on Dyspareunia Treatment Market